Please try another search
© Reuters
By Davit Kirakosyan
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Dollar General, Warner Music, Xcel Energy, and Ginkgo Bioworks.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
Two Wall Street firms downgraded Dollar General (NYSE:DG) after the company reported a Q1 EPS and revenue miss, which resulted in a share price drop of more than 19% yesterday.
Piper Sandler downgraded the company to Neutral from Overweight and cut its price target to $178.00 from $275.00 on somewhat inexplicable sales/comp weakness, lack of conviction for a near-term rebound, and concerns that guidance wasn't reduced enough.
While noting that Dollar General highlights well-known macro headwinds, Piper Sandler cannot explain why it is seeing a more material impact (and lack of trade-down) versus other retailers serving lower-income customers.
Meanwhile, Atlantic Equities downgraded the company to Neutral from Overweight with a price target of $170.00 following the commentary on the most recent changes to consumer behavior. The firm highlighted that Q1 showed a steeper rate of change in Dollar General's core customer base.
Atlantic Equities downgraded Warner Music Group (NASDAQ:WMG) to Neutral from Overweight and cut its price target of $26.00 from $39.00, as InvestingPro reported in real time.
The firm mentioned two key developments over the past six months: (1) loss of streaming share means recorded music streaming revenues are growing slower than expected, and (2) the rapid development of AI-created music is placing a major cloud over the whole sector.
Xcel Energy (NASDAQ:XEL) shares fell more than 2% premarket today after the company was downgraded at two Wall Street firms.
JPMorgan downgraded the stock to Neutral from Overweight and cut its price target to $68.00 from $79.00. Meanwhile, Wolfe Research downgraded to Peerperform from Outperform.
Goldman Sachs downgraded Ginkgo Bioworks (NYSE:DNA) to Sell from Neutral and cut its price target of $1.25 from $3.00. Shares fell nearly 5% premarket today.
While the bank thinks the end market shift towards Biopharma and Agriculture is a sound long-term strategy, it believes the macro environment and the softening spend seen in the biopharma end market may result in slower new program growth for the company.
In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.
Start your free 7-day trial now.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Author
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.